In cases of delayed screening results not only for NPM1 but also for the other above-mentioned key mutations, important information regarding the prognostic classification of the AML patient is lacking at the critical time point for making a treatment decision on whether to transplant the patient or not. The gene discussed is NPM1; the disease is acute myeloid leukemia.